SCYNEXIS, Inc. SCYX · Stock Open SCYNEXIS, Inc. in new tab
SCYNEXIS, Inc. Analysis (SCYX)
Is SCYNEXIS, Inc. a good investment? SCYNEXIS, Inc. (SCYX) is currently trading at 4.39 USD. Market analysts have a consensus price target of 36.55 USD. This suggests a potential upside from current levels.
Earnings Schedule: SCYNEXIS, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -2.32.
Investor FAQ
Does SCYNEXIS, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is SCYNEXIS, Inc.?
SCYNEXIS, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -0.91.
Company Profile
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Split Date | Split Ratio to 1 |
|---|---|
| July 17, 2020 | 1:10 |
| June 1, 2026 | 0.12 |
Community Discussion